<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37545141</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2005-6648</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>The Korean journal of internal medicine</Title><ISOAbbreviation>Korean J Intern Med</ISOAbbreviation></Journal><ArticleTitle>Long-term renal outcomes of patients with non-proliferative lupus nephritis.</ArticleTitle><Pagination><StartPage>769</StartPage><EndPage>776</EndPage><MedlinePgn>769-776</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3904/kjim.2022.339</ELocationID><Abstract><AbstractText Label="BACKGROUND/AIMS">Although non-proliferative lupus nephritis (LN) (class I, II or V) has been considered as a less severe type of LN, data on long-term renal prognosis are limited. We investigated the long-term outcomes and prognostic factors in non-proliferative LN.</AbstractText><AbstractText Label="METHODS">We retrospectively reviewed patients with systemic lupus erythematosus who were diagnosed with LN class I, II, V, or II + V by kidney biopsy from 1997 to 2021. A poor renal outcome was defined as an estimated glomerular filtration rate (eGFR) of &lt; 60 mL/min/1.73 m2.</AbstractText><AbstractText Label="RESULTS">We included 71 patients with non-proliferative LN (class I = 4; class II = 17; class V = 48; class II+V = 2), and the overall rate of poor renal outcomes was 29.6% (21/71). The univariate analysis indicated that older age, low eGFR at 6 or 12 months, failure to reach complete remission at 6 months, and LN chronicity score &gt; 4 or activity score &gt; 6 were significantly associated with poor renal outcomes. The multivariate analysis revealed that low eGFR at 6 months (HR 0.971, 95% CI 0.949-0.991; p = 0.014) was significantly associated with poor renal outcomes.</AbstractText><AbstractText Label="CONCLUSION">Poor renal outcomes occurred in approximately 30% of patients with non-proliferative LN after long-term follow-up. More active management may be needed for non-proliferative LN, especially for patients with eGFR &lt; 60 mL/ min/1.73 m2 at 6 months follow-up after LN diagnosis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Eun-Song</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Soo Min</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Ji Seon</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yong-Gil</ForeName><Initials>YG</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Chang-Keun</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Bin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Seokchan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2022IP0062-1</GrantID><Agency>Asan Institute for Life Sciences, Asan Medical Center</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Korean J Intern Med</MedlineTA><NlmUniqueID>8712418</NlmUniqueID><ISSNLinking>1226-3303</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Korean J Intern Med. 2023 Sep;38(5):581-582</RefSource><PMID Version="1">37680095</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008181" MajorTopicYN="Y">Lupus Nephritis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007668" MajorTopicYN="N">Kidney</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007676" MajorTopicYN="Y">Kidney Failure, Chronic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001706" MajorTopicYN="N">Biopsy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Lupus nephritis</Keyword><Keyword MajorTopicYN="N">Renal outcome</Keyword><Keyword MajorTopicYN="N">Systemic lupus erythematosus</Keyword></KeywordList><CoiStatement>
<b>Conflicts of interest</b>
. The authors disclose no conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>11</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>7</Day><Hour>2</Hour><Minute>10</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37545141</ArticleId><ArticleId IdType="pmc">PMC10493439</ArticleId><ArticleId IdType="doi">10.3904/kjim.2022.339</ArticleId><ArticleId IdType="pii">kjim.2022.339</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bernatsky S, Boivin JF, Joseph L, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54:2550&#x2013;2557.</Citation><ArticleIdList><ArticleId IdType="pubmed">16868977</ArticleId></ArticleIdList></Reference><Reference><Citation>Doria A, Iaccarino L, Ghirardello A, et al. Long-term prognosis and causes of death in systemic lupus erythematosus. Am J Med. 2006;119:700&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">16887417</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomback AS, Appel GB. Updates on the treatment of lupus nephritis. J Am Soc Nephrol. 2010;21:2028&#x2013;2035.</Citation><ArticleIdList><ArticleId IdType="pubmed">21051743</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajema IM, Wilhelmus S, Alpers CE, et al. Revision of the International Society of Nephrology/Renal Pathology Society classification for lupus nephritis: clarification of definitions, and modified National Institutes of Health activity and chronicity indices. Kidney Int. 2018;93:789&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pubmed">29459092</ArticleId></ArticleIdList></Reference><Reference><Citation>Moroni G, Quaglini S, Gallelli B, Banfi G, Messa P, Ponticelli C. The long-term outcome of 93 patients with proliferative lupus nephritis. Nephrol Dial Transplant. 2007;22:2531&#x2013;2539.</Citation><ArticleIdList><ArticleId IdType="pubmed">17510096</ArticleId></ArticleIdList></Reference><Reference><Citation>Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971&#x2013;980.</Citation><ArticleIdList><ArticleId IdType="pubmed">14999109</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343:1156&#x2013;1162.</Citation><ArticleIdList><ArticleId IdType="pubmed">11036121</ArticleId></ArticleIdList></Reference><Reference><Citation>Daleboudt GM, Bajema IM, Goemaere NN, van Laar JM, Bruijn JA, Berger SP. The clinical relevance of a repeat biopsy in lupus nephritis flares. Nephrol Dial Transplant. 2009;24:3712&#x2013;3717.</Citation><ArticleIdList><ArticleId IdType="pubmed">19622571</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Ying KY, Lau CS, et al. Treatment of pure membranous lupus nephropathy with prednisone and azathioprine: an open-label trial. Am J Kidney Dis. 2004;43:269&#x2013;276.</Citation><ArticleIdList><ArticleId IdType="pubmed">14750092</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin HA, Illei GG. Membranous lupus nephritis. Lupus. 2005;14:65&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">15732291</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan TM, Li FK, Hao WK, et al. Treatment of membranous lupus nephritis with nephrotic syndrome by sequential immunosuppression. Lupus. 1999;8:545&#x2013;551.</Citation><ArticleIdList><ArticleId IdType="pubmed">10483033</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck LH, Jr, Salant DJ. Treatment of membranous lupus nephritis: where are we now? J Am Soc Nephrol. 2009;20:690&#x2013;691.</Citation><ArticleIdList><ArticleId IdType="pubmed">19279123</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn BH, McMahon MA, Wilkinson A, et al. American College of Rheumatology American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken) 2012;64:797&#x2013;808.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3437757</ArticleId><ArticleId IdType="pubmed">22556106</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ, Collaborative Study Group Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol. 2008;3:46&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2390978</ArticleId><ArticleId IdType="pubmed">18003764</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney Disease Outcomes Quality Initiative (K/DOQI) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43(5 Suppl 1):S1&#x2013;S290.</Citation><ArticleIdList><ArticleId IdType="pubmed">15114537</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening JJ, D&#x2019;Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol. 2004;15:241&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">14747370</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega LM, Schultz DR, Lenz O, Pardo V, Contreras GN. Review: lupus nephritis: pathologic features, epidemiology and a guide to therapeutic decisions. Lupus. 2010;19:557&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">20089610</ArticleId></ArticleIdList></Reference><Reference><Citation>MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis. 2006;48:8&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pubmed">16797382</ArticleId></ArticleIdList></Reference><Reference><Citation>Teplitsky V, Shoenfeld Y, Tanay A. The renin-angiotensin system in lupus: physiology, genes and practice, in animals and humans. Lupus. 2006;15:319&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">16830877</ArticleId></ArticleIdList></Reference><Reference><Citation>Donadio JV, Jr, Hart GM, Bergstralh EJ, Holley KE. Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus. 1995;4:109&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">7795613</ArticleId></ArticleIdList></Reference><Reference><Citation>Mok CC, Wong RW, Lau CS. Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long-term outcome. Am J Kidney Dis. 1999;34:315&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">10430980</ArticleId></ArticleIdList></Reference><Reference><Citation>Esdaile JM, Abrahamowicz M, MacKenzie T, Hayslett JP, Kashgarian M. The time-dependence of long-term prediction in lupus nephritis. Arthritis Rheum. 1994;37:359&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">8129791</ArticleId></ArticleIdList></Reference><Reference><Citation>Tam LS, Li EK, Lai FM, Chan YK, Szeto CC. Mesangial lupus nephritis in Chinese is associated with a high rate of transformation to higher grade nephritis. Lupus. 2003;12:665&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">14514128</ArticleId></ArticleIdList></Reference><Reference><Citation>Lentz RD, Michael AF, Friend PS. Membranous transformation of lupus nephritis. Clin Immunol Immunopathol. 1981;19:131&#x2013;138.</Citation><ArticleIdList><ArticleId IdType="pubmed">7011616</ArticleId></ArticleIdList></Reference><Reference><Citation>Bomback AS. Nonproliferative forms of lupus nephritis: an overview. Rheum Dis Clin North Am. 2018;44:561&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8404975</ArticleId><ArticleId IdType="pubmed">30274623</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsuwaida AO. The clinical significance of serial kidney biopsies in lupus nephritis. Mod Rheumatol. 2014;24:453&#x2013;456.</Citation><ArticleIdList><ArticleId IdType="pubmed">24251991</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang GB, Xu ZJ, Liu HF, Zhou QG, Zhou ZM, Jia N. Changes in pathological pattern and treatment regimens based on repeat renal biopsy in lupus nephritis. Chin Med J (Engl) 2012;125:2890&#x2013;2894.</Citation><ArticleIdList><ArticleId IdType="pubmed">22932086</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayodele OE, Okpechi IG, Swanepoel CR. Predictors of poor renal outcome in patients with biopsy-proven lupus nephritis. Nephrology (Carlton) 2010;15:482&#x2013;490.</Citation><ArticleIdList><ArticleId IdType="pubmed">20609103</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin HA, 3rd, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994;45:544&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pubmed">8164443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zahab M, Fouda MA, Elhendy Y, et al. Treatment outcomes of proliferative vs. non-proliferative adult lupus nephritis: a 10-year follow-up. Cureus. 2021;13:e16955.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8418876</ArticleId><ArticleId IdType="pubmed">34513521</ArticleId></ArticleIdList></Reference><Reference><Citation>Duran E, Y&#x131;ld&#x131;r&#x131;m T, Taghiyeva A, et al. Differences and similarities of proliferative and non-proliferative forms of biopsy-proven lupus nephritis: single centre, cross-disciplinary experience. Lupus. 2022;31:1147&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9277329</ArticleId><ArticleId IdType="pubmed">35658643</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>